厄洛替尼对非小细胞肺癌患者免疫细胞影响的研究

Effect of erlotinib on immune cells in patients with non-small cell lung cancer

目的探讨厄洛替尼用于晚期非小细胞肺患者,对患者免疫细胞及肿瘤标志物的影响。方法选取2015年2月～2018年2月我院收治的确诊为晚期非小细胞肺癌患者120例,随机分为两组,对照组为EGFR野生型、突变型或突变情况不明患者,应用含铂两药方案(TP)治疗,研究组为EGFR敏感突变患者,单用厄洛替尼治疗。回顾性分析两组患者的外周血检验免疫细胞及肿瘤标志物结果,进行对比分析。结果治疗前两组患者CD_4^+、CD_8^+、CD_4^+/CD_8^+无明显差异(P>0.05),治疗后研究组患者CD_4^+、CD_8^+、CD_4^+/CD_8^+显著高于对照组(P<0.05);研究组治疗有效率为83.33%,显著高于对照组的51.67%,差异有统计学意义(P<0.05);CEA、CYFAR21-1、CA125水平比较,差异无统计学意义(P>0.05);治疗后两组患者血清CEA、CYFAR21-1、CA125水平均较治疗前显著降低,且研究组降低程度高于对照组,差异有统计学意义(P<0.05)。结论厄洛替尼对比化疗可以增强患者的细胞免疫功能,提高治疗有效率,应作为首选治疗方案。厄洛替尼对比化疗,对肺癌患者的标志物影响更显著,提示对比化疗对肿瘤细胞的杀伤能力更强。

Objective To investigate the effect of erlotinib on the immune cells and tumor markers in patients with ad- vanced non-small cell lung disease. Methods A total of 120 patients with advanced non-small cell lung cancer who were admitted in our hospital from February 2015 to February 2018 were selected and were randomly divided into two groups. The patients with EGFR wild type mutant or unclear mutation in the control group were treated with platinum- based chemotherapy regimens（TP）. The EGFR-sensitive mutation patients in the study group were treated with erlotinib alone. The results of peripheral blood test of immune cells and tumor markers in both groups were retrospectively ana- lyzed and comparatively analyzed. Results There was no significant difference in CD4＋, CD8＋, and CD4＋/CD8＋ before treatment（P〉0.05）. After treatment, CD4＋, CD8＋, and CD4＋/CD8＊ in the study group were significantly higher than those in the control group （P〈0.05）. The treatment effective rate in the study group was 83.33%, significantly higher than that in the control group（51,67%）, and the data between the two groups were statistically significant difference （P〈0.05）. There was no statistically significant difference in CEA, CYFAR21-1, CA125 levels（P〉0.05）. Serum CEA, CYFAR21-I, and CA125 levels in the two groups after treatment were significantly lower than those before treatment, and the reduc- tion degree in the study group was higher than that in the control group. The difference between the two groups was statistically significant（P〈0.05）. Conclusion Erlotinib comparative chemo therapy can enhance the cellular immune function of patients and increase the efficiency of treatment, which should be the first choice for treatment. It has more significant effect on the markers of lung cancer patients, suggesting that comparative chemotherapy has a greater ability to kill tumor cells.